|
1
|
Yu Z, Ding YL, Lu F, Miao LY, Shen ZY and
Ye WX: Warfarin dosage adjustment strategy in Chinese population.
Int J Clin Exp Med. 8:9904–9910. 2015.PubMed/NCBI
|
|
2
|
Baglin TP, Keeling DM and Watson HG;
British Committee for Standards in Haematology, : Guidelines on
oral anticoagulation (warfarin): Third edition-2005 update. Br J
Haematol. 132:277–285. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park SM, Lee JK, Chun SI, Lee HI, Kwon SU,
Kang DW and Kim JS: VKORC1 and CYP2C9 genotype variations in
relation to warfarin dosing in Korean stroke patients. J Stroke.
15:115–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krishna Kumar D, Shewade DG, Loriot MA,
Beaune P, Balachander J, Sai Chandran BV and Adithan C: Effect of
CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on Warfarin
maintenance dose and explicating a new pharmacogenetic algorithm in
South Indian population. Eur J Clin Pharmacol. 70:47–56. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lou Y, Hua L, Han L, Li Y, Zhang X, Tang
M, Yu H, Liu Z, Wang W, Xu J, et al: Establishment and preliminary
validation of Warfarin maintenance dose algorithm in Chinese Han
Population. Zhonghua Xin Xue Guan Bing Za Zhi. 42:384–388. 2014.(In
Chinese). PubMed/NCBI
|
|
6
|
Routledge PA, Davies DM, Bell SM, Cavanagh
JS and Rawlins MD: Predicting patients' warfarin requirements.
Lancet. 2:854–855. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Liu R, Luo ZY, Yan H, Huang WH, Yin
JY, Mao XY, Chen XP, Liu ZQ, Zhou HH and Zhang W: Comparison of the
predictive abilities of pharmacogenetics-based warfarin dosing
algorithms using seven mathematical models in Chinese patients.
Pharmacogenomics. 16:583–590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aithal GP, Day CP, Kesteven PJ and Daly
AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with
warfarin dose requirement and risk of bleeding complications.
Lancet. 353:717–719. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bodin L, Verstuyft C, Tregouet DA, Robert
A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P,
Becquemont L and Loriot MA: Cytochrome P450 2C9 (CYP2C9) and
vitamin K epoxide reductase (VKORC1) genotypes as determinants of
acenocoumarol sensitivity. Blood. 106:135–140. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sconce EA, Khan TI, Wynne HA, Avery P,
Monkhouse L, King BP, Wood P, Kesteven P, Daly AK and Kamali F: The
impact of CYP2C9 and VKORC1 genetic polymorphism and patient
characteristics up-on warfarin dose requirements: Proposal for a
new dosing regiment. Blood. 106:2329–2333. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rost S, Fregin A, Ivaskevicius V,
Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E,
Scharrer I, Tuddenham EG, et al: Mutations in VKORC1 cause warfarin
resistance and multiple coagulation factor deficiency type 2.
Nature. 427:537–541. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou SF, Zhou ZW and Huang M:
Polymorphisms of human cytochrome P450 2C9 and the functional
relevance. Toxicology. 278:165–188. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Namazi S, Azarpira N, Hendijani F,
Khorshid MB, Vessal G and Mehdipour AR: The impact of genetic
polymorphisms and patient characteristics on warfarin dose
requirements: A cross-sectional study in Iran. Clin Ther.
32:1050–1060. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Higashi MK, Veenstra DL, Kondo LM,
Wittkowsky AK, Srinouanprachanh SL, Farin FM and Rettie AE:
Association between CYP2C9 genetic variants and anticoagulation
related outcomes during warfarin therapy. JAMA. 287:1690–1698.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lane S, Al-Zubiedi S, Hatch E, Matthews I,
Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K,
et al: The population pharmacokinetics of R- and S-warfarin: Effect
of genetic and clinical factors. Br J Clin Pharmacol. 73:66–76.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rieder MJ, Reiner AP and Rettie AE:
Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for
predicting warfarin maintenance dose. J Thromb Haemost.
5:2227–2234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chung JE, Lee KE, Chang BC and Gwak HS:
Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and
stable warfarin doses. Gene. 641:68–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hamberg AK, Hellman J, Dahlberg J, Jonsson
EN and Wadelius M: A Bayesian decision support tool for efficient
dose individualization of warfarin in adults and children. BMC Med
Inform Decis Mak. 15:72015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
International Warfarin Pharmacogenetics
Consortium, ; Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE,
Lee MT, Limdi NA, Page D, Roden DM, et al: Estimation of the
warfarin dose with clinical and pharmacogenetic data. N Engl J Med.
360:753–764. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cui GL, Ding H, Xu YJ, et al: High
resolution melting curves (HRM) in the prevention of Warfarin
initiation guide measurement genotyping and clinical application of
various genotyping methods. Chin J Cardiol. 40:477–481. 2012.
|
|
21
|
Deng S, Zhu G, Liu F, Zhang H, Qin X, Li L
and Zhiyi H: CYP4F2 gene V433M polymorphism is associated with
ischemic stroke in the male Northern Chinese Han population. Prog
Neuropsychopharmacol Biol Psychiatry. 34:664–668. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fung E, Patsopoulos NA, Belknap SM,
O'Rourke DJ, Robb JF, Anderson JL, Shworak NW and Moore JH: Effect
of genetic variants, especially CYP2C9 and VKORC1, on the
pharmacology of Warfarin. Semin Thromb Hemost. 38:893–904. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirsh J, Dalen JE, Anderson DR, Poller L,
Bussey H, Ansell J, Deykin D and Brandt JT: Oral anticoagulants:
Mechanism of action, clinical effectiveness, and optimal
therapeutic range. Chest. 114 5 Suppl:445S–469S. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shahin MH, Cavallari LH, Perera MA,
Khalifa SI, Misher A, Langaee T, Patel S, Perry K, Meltzer DO,
McLeod HL and Johnson JA: VKORC1 Asp36Tyr geographic distribution
and its impact on warfarin dose requirements in Egyptians. Thromb
Haemost. 109:1045–1050. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mushiroda T, Ohnishi Y, Saito S, Takahashi
A, Kikuchi Y, Saito S, Shimomura H, Wanibuchi Y, Suzuki T, Kamatani
N and Nakamura Y: Association of VKORC1 and CYP2C9 polymorphisms
with warfarin dose requirements in Japanese patients. J Hum Genet.
51:249–253. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen J, Shao L, Gong L, Luo F, Wang J, Shi
Y, Tan Y, Chen Q, Zhang Y, Hui R and Wang Y: A
pharmacogenetics-based Warfarin maintenance dosing algorithm from
Northern Chinese patients. PLoS One. 9:e1052502014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhuang WF, Chen YH, Luo RP, et al:
Evaluation on the stable dose prediction accuracy of Warfarin
anticoagulant therapy by pharmacogenetics among Shanghai patients.
Lab Med. 30:697–702. 2015.
|
|
28
|
Yu LP, Song HT, Zeng ZY, Wang QM and Qiu
HF: Validation and comparison of pharmacogenetics-based warfarin
dosing algorithms in Han Chinese Patients. Zhonghua Xin Xue Guan
Bing Za Zhi. 40:614–619. 2012.(In Chinese). PubMed/NCBI
|
|
29
|
Roper N, Storer B, Bona R and Fang M:
Validation and comparison of pharmacogenetics-based warfarin dosing
algorithms for application of pharmacogenetic testing. J Mol Diagn.
12:283–291. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao S, Zhao H, Wang X, Gao C, Qin Y, Cai
H, Chen B and Cao J: Factors influencing medication knowledge and
beliefs on warfarin adherence among patients with atrial
fibrillation in China. Patient Prefer Adherence. 11:213–220. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Han ZH, Ren XJ and Wang Y: Anticoagulation
management of patients with long-term warfarin therapy after valve
replacement during the perioperative period of pacemaker
implantation. Int J Clin Exp Med. 6:594–598. 2013.PubMed/NCBI
|
|
32
|
Hudson M, Richard H and Pilote L:
Differences in outcomes of patients with congestive heart failure
prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory
drugs: Population based study. BMJ. 330:13702005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cleland JG, Findlay I, Jafri S, Sutton G,
Falk R, Bulpitt C, Prentice C, Ford I, Trainer A and Poole-Wilson
PA: The Warfarin/Aspirin Study in Heart failure (WASH): A
randomized trial comparing antithrombotic strategies for patients
with heart failure. Am Heart J. 148:157–164. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu Y, Won KA, Nelson BJ, Qi D, Rausch DJ
and Asinger RW: Characteristics of the amiodarone-warfarin
interaction during long-term follow-up. Am J Health Syst Pharm.
65:947–952. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhong SL, Liu Y, Yu XY, Xu D, Tan HH, Lin
QX, Yang M, Lao HY and Lin SG: The influence of genetic
polymorphisms and interacting drugs on initial response to warfarin
in Chinese patients with heart valve replacement. Eur J Clin
Pharmacol. 67:581–590. 2011. View Article : Google Scholar : PubMed/NCBI
|
